AbbVie (ABBV) Change in Receivables (2012 - 2026)

AbbVie has disclosed Change in Receivables across 15 years of filings, most recently posting -$87.0 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 105.88% year-over-year to -$87.0 million; the TTM figure through Mar 2026 stood at -$76.0 million (down 113.33% YoY), while the FY2025 annual figure was $1.5 billion, up 819.81% from the prior year.
• Change in Receivables advanced to -$87.0 million in Q1 2026, from -$162.0 million in the prior quarter.
• Over the last five years, Change in Receivables for ABBV reached as high as $1.5 billion in Q1 2025 and fell as low as -$387.0 million in Q4 2024.
• The 5-year median for Change in Receivables is $17.0 million (2025), against an average of $152.1 million.
• The widest YoY moves for Change in Receivables: up 260.0% in 2024, down 17100.0% in 2024.
• A 5-year view of Change in Receivables shows it stood at $416.0 million in 2022, then tumbled by 181.49% to -$339.0 million in 2023, then declined by 14.16% to -$387.0 million in 2024, then jumped by 58.14% to -$162.0 million in 2025, then jumped by 46.3% to -$87.0 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$87.0 million, -$162.0 million, and $156.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.